What is Alevio?
Alevio Spine operates at the intersection of orthopedics and minimally invasive surgery, focusing specifically on the treatment of sacroiliac joint dysfunction. By developing proprietary technologies such as the SI-Cure Implant System, the company provides clinicians with robust tools to address chronic low back pain. Their market strategy integrates product innovation with patient education, ensuring that healthcare providers have access to scalable, effective solutions for complex spinal conditions. As a key player in the medical device sector, Alevio continues to refine its surgical portfolio to meet the growing demand for outpatient-friendly, high-efficacy orthopedic procedures.
How much funding has Alevio raised?
Alevio has raised a total of $420K across 2 funding rounds:
Debt
$150K
Debt
$270K
Debt (2020): $150K with participation from PPP
Debt (2021): $270K led by PPP
Key Investors in Alevio
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Alevio?
With this late-stage capital, Alevio is well-positioned to accelerate its commercial expansion and deepen its penetration into the global spine surgery market. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities and the expansion of clinical training programs for surgeons. By leveraging its current market momentum, the company aims to solidify its footprint in the sacroiliac joint treatment space, potentially exploring further R&D initiatives to diversify its surgical offerings. The focus remains on long-term value creation through clinical excellence and the continued adoption of its minimally invasive platforms by major hospital networks.
See full Alevio company page
